Total medical devices industry venture financing deals worth $213m were announced in Asia-Pacific in August 2022, led by $52.57m venture financing of CureApp, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 18.6% over the previous month of $261.76m and a drop of 56.05% when compared with the last 12-month average of $484.64m.
Asia-Pacific held an 18.68% share of the global medical devices industry venture financing deal value that totalled $1.14bn in August 2022. With a 13.19% share and deals worth $150.41m, China was the top country in Asia-Pacific’s venture financing deal value across medical devices industry.
In terms of venture financing deal activity, Asia-Pacific recorded 37 deals during August 2022, marking an increase of 2.78% over the previous month and a flat growth over the 12-month average. China recorded 29 deals during the month.
Asia-Pacific medical devices industry venture financing deals in August 2022: Top deals
The top five medical devices industry venture financing deals accounted for 66.2% of the overall value during August 2022.
The combined value of the top five medical devices venture financing deals stood at $140.97m, against the overall value of $213m recorded for the month.
The top five medical devices industry venture financing deals of August 2022 tracked by GlobalData were:
1) The Carlyle Group’s $52.57m venture financing deal with CureApp
2) The $29.58m venture financing of Cygnus Biosciences (Beijing) by China State-owned Enterprise Structural Adjustment Fund Phase II and Wuxi Guolian Guokang Health Industry Investment Center
3) BASF Venture Capital (Shanghai), Jinyu Bogor Investment Management Co. and Qiming Venture Partners’s $29.19m venture financing deal with Prismlab China
4) The $14.83m venture financing of Suzhou Yatong Biomedical Technology by Borun Capital, Guolian Xinchuang, Hongshi Capital and Xingze Capital
5) Gaorong Capital, Kaitai Capital, Shanghai Lichen Private Equity Fund Management and Virtus Inspire Ventures’s $14.81m venture financing deal with Crystal Nucleus Biomedical Technology (Nanjing)